OTC Rogaine denied Waxman/Hatch exclusivity by federal court.
This article was originally published in The Tan Sheet
Executive Summary
ROGAINE EXCLUSIVITY: FDA "MERELY DESCRIBED" Rx-TO-OTC SWITCH NDA data requirements in a 1992 meeting with Upjohn representatives, according to Judge Robert Holmes Bell's April 30 decision to deny the company's motion for preliminary injunction to prevent generic manufacturers from selling private-label minoxidil 2% topical solution. Judge Bell also "dissolved" a temporary restraining order preventing the generic firms from introducing their products ("The Tan Sheet" April 22, p. 8).
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning